Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 Case reports

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 4, 2013, Pages 493-495

  Broccoli, Alessandro ^a   Derenzini, Enrico ^a   Pellegrini, Cinzia ^a   Narducci, Riccardo ^a   Stefani, Giulia ^a   Casadei, Beatrice ^a   Argnani, Lisa ^a   Zinzani, Pier Luigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Anaplastic large cell lymphoma; Anaplastic lymphoma kinase negative; Brentuximab vedotin; Cutaneous T cell lymphoma; Immunotherapy

Indexed keywords

ANTICOAGULANT AGENT; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CD2 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IFOSFAMIDE; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; OXALIPLATIN; PACLITAXEL; PARACETAMOL; PREDNISONE; STEROID; VINCRISTINE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD VESSEL OCCLUSION; BONE MARROW BIOPSY; BRONCHOSCOPY; BRONCHUS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INFILTRATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CHILL; COMORBIDITY; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ECHOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HISTOPATHOLOGY; HUMAN; HYPESTHESIA; ILIAC BONE; INCONTINENCE; INGUINAL LYMPH NODE; INGUINAL REGION; IRON DEFICIENCY ANEMIA; LARGE CELL LYMPHOMA; LIMB WEAKNESS; LUNG LOBE; LUNG NODULE; LYMPH NODE BIOPSY; LYMPHADENOPATHY; LYMPHEDEMA; MALE; MEDIASTINUM LYMPH NODE; MICROCYTIC ANEMIA; MULTIPLE CYCLE TREATMENT; OCCULT BLOOD TEST; ORAL MUCOSITIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RADIOSENSITIVITY; SAPHENOUS VEIN; SKIN DEFECT; STOMACH ANTRUM; SWELLING; TREATMENT DURATION; TREATMENT RESPONSE; WHOLE BODY CT;

ANAPLASTIC LARGE CELL LYMPHOMA; ANAPLASTIC LYMPHOMA KINASE NEGATIVE; BRENTUXIMAB VEDOTIN; CUTANEOUS T-CELL LYMPHOMA; IMMUNOTHERAPY;

AGED; FEMALE; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, LARGE-CELL, ANAPLASTIC; LYMPHOMA, T-CELL, CUTANEOUS; MALE; RECURRENCE;

EID: 84880716147     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.03.008     Document Type: Article

References (9)

1. K.J. Savage, N.L. Harris, and J.M. Vose ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project Blood 111 2008 5496 5504
2. H. Tilly, P. Gaulard, and E. Lepage Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome Blood 90 1997 3727 3734 (Pubitemid 27473445)
3. J. Vose, J. Armitage, and D. Weisenburger International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes J Clin Oncol 26 2008 4124 4130
4. C.E. Dearden, R. Johnson, and R. Pettengell Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma) Br J Haematol 153 2011 451 485
5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin Lymphoma, Version 2 2012 [Web site]. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed September 4, 2012.
6. T. Kewalramani, A.D. Zelenetz, and J. Teruya-Feldstein Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma Br J Haematol 134 2006 202 207 (Pubitemid 43893913)
7. A. Younes, N.L. Bartlett, and J.P. Leonard Brentuximab vedotin (SGN35) for relapsed CD30-positive lymphomas N Engl J Med 363 2010 1812 1821
8. B. Pro, R. Advani, and P. Brice Brentuximab vedotin (SGN35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study J Clin Oncol 30 2012 2190 2196
9. A. Gibb, C. Jones, and A. Bloor Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK Centre Haematologica 98 2012 611 614